# Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

> **NCT05592418** · PHASE2 · COMPLETED · sponsor: **AIM ImmunoTech Inc.** · enrollment: 80 (actual)

## Conditions studied

- Post COVID-19 Condition
- Long COVID

## Interventions

- **DRUG:** Rintatolimod
- **OTHER:** Placebo / Normal Saline

## Key facts

- **NCT ID:** NCT05592418
- **Lead sponsor:** AIM ImmunoTech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-30
- **Primary completion:** 2023-11-17
- **Final completion:** 2023-11-30
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05592418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05592418, "Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05592418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*